Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 7687 results

  1. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  2. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  3. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 16 July 2025

    NICE guideline
    In development

  5. Iptacopan for treating complement 3 glomerulopathy ID6283

    In development [GID-TA11331] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 26 November 2024.

    Technology appraisal guidance
    In consultation

  7. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Prolonged-release diazoxide choline for treating Prader-Willi syndrome [ID1389]

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

    In development [GID-TA11424] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

    In development [GID-TA11106] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]

    In development [GID-TA10611] Expected publication date: 18 December 2024

    Technology appraisal guidance
    In development

  12. Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082

    In development [GID-TA10969] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

    In development [GID-TA10912] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  14. Urinary Tract Infection (recurrent): antimicrobial prescribing

    In development [GID-NG10422] Expected publication date: 12 December 2024

    NICE guideline
    In development

  15. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: TBC

    Technology appraisal guidance
    In development